| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/05/2013 | CA2701116C Alkoxy compounds for disease treatment |
| 02/05/2013 | CA2557766C Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 02/05/2013 | CA2492273C 3, 10, and 12a substituted tetracycline compounds |
| 02/05/2013 | CA2428176C Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2013 | CA2352454C Peptide-based vaccine for influenza |
| 01/31/2013 | WO2013016677A1 N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof |
| 01/31/2013 | WO2013016252A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| 01/31/2013 | WO2013016197A1 Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators |
| 01/31/2013 | WO2013016125A1 Compositions and methods for the treatment of ocular surface allergies |
| 01/31/2013 | WO2013015984A1 N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS |
| 01/31/2013 | WO2013014629A1 Pharmaceutical compositions comprising pyrrole diones and their use to inhibit angiogenesis |
| 01/31/2013 | WO2012166932A3 Treating tear film disorders with mesenchymal stem cells |
| 01/31/2013 | WO2012148930A3 Oxidative retinal diseases |
| 01/31/2013 | US20130030057 METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| 01/31/2013 | US20130030043 Treating glaucoma, cardiovascular diseases, and renal diseases |
| 01/31/2013 | US20130030032 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 01/31/2013 | US20130030026 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| 01/31/2013 | US20130030014 N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS |
| 01/31/2013 | US20130030011 Compounds for the reduction of beta-amyloid production |
| 01/31/2013 | US20130030008 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| 01/31/2013 | US20130030000 Pharmaceutical compositions for the treatment of pain and other indications |
| 01/31/2013 | US20130029995 Substituted Bicyclic Aromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands |
| 01/31/2013 | US20130029994 N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | US20130029992 N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof |
| 01/31/2013 | US20130029977 Fused substituted aminopyrrolidine derivative |
| 01/31/2013 | US20130029970 CB Receptor Agonists |
| 01/31/2013 | US20130029968 Indazoles |
| 01/31/2013 | US20130029963 1,2,4-triazine-4-amine derivatives |
| 01/31/2013 | US20130029961 Substituted Heterocyclic Aza Compounds |
| 01/31/2013 | US20130029952 Combination of Azelastine and Mometasone for Nasal Administration |
| 01/31/2013 | US20130029951 Combination of Azelastine and Ciclesonide for Nasal Administration |
| 01/31/2013 | US20130029939 Novel glucokinase activators and methods of using same |
| 01/31/2013 | US20130029919 Two part formulation system for opthalmic delivery |
| 01/31/2013 | US20130028958 Beta-carbolines for use in the treatment of hearing loss and vertigo |
| 01/31/2013 | US20130028923 Kdr peptides and vaccines comprising the same |
| 01/31/2013 | US20130028920 Stabilized antibody preparations and uses thereof |
| 01/31/2013 | US20130028911 Vascular endothelial cell growth factor antagonists |
| 01/31/2013 | US20130028889 Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| 01/31/2013 | US20130028877 LACTOBACILLUS JOHNSONII La1 NCC533 (CNCM I-1225) AND IMMUNE DISORDERS |
| 01/31/2013 | US20130028874 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| 01/31/2013 | US20130028870 Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease |
| 01/31/2013 | US20130028850 Topical tetracycline compositions |
| 01/31/2013 | US20130028836 Chlorotoxin polypeptides and conjugates and uses thereof |
| 01/31/2013 | CA2843273A1 N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof |
| 01/31/2013 | CA2843245A1 N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | CA2842756A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| 01/31/2013 | CA2842528A1 Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators |
| 01/31/2013 | CA2842099A1 Antigen binding constructs |
| 01/31/2013 | CA2840727A1 Compositions and methods for the treatment of ocular surface allergies |
| 01/30/2013 | EP2550013A1 Treating allergy with detoxified e. coli heat-labile enterotoxin |
| 01/30/2013 | EP2549989A1 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media |
| 01/30/2013 | CN102905714A Composition comprising coumestrol or bean extract containing coumestrol |
| 01/30/2013 | CN102905708A A3ar agonists for the treatment of uveitis |
| 01/30/2013 | CN102905697A Compounds targeting VEGF and/or HIF pathway such as sorafenib or vatalanib for use in treatment of otitis media |
| 01/30/2013 | CN102898417A Benzo-hexahydric nitrogenous heterocycle derivative |
| 01/30/2013 | CN102898416A 5-substituted quinazolinone derivatives as anti-cancer agents |
| 01/30/2013 | CN102898380A Amine salts of a CRTH2 antagonist |
| 01/30/2013 | CN102898284A 3-allyl-[1,1'-biphenyl]-4-phenol, derivatives, preparation methods and uses thereof |
| 01/30/2013 | CN102895673A Treatment of eye disorders |
| 01/30/2013 | CN102895663A Compositions containing EGFL 7 antagonist for modulating vascular development and methods |
| 01/30/2013 | CN102895635A Preparation technology and production method for integrated new formulation of astragalus center-fortifying decoction |
| 01/30/2013 | CN102895627A Preparation technology and production method for integrated new formulation of radix bupleuri, cassia twig and dry ginger decoction |
| 01/30/2013 | CN102895626A Preparation technology and production method for integrated new formulation of radix bupleuri decoction minus pinellia ternate plus snakegourd root |
| 01/30/2013 | CN102895624A Preparation technology and production method for integrated new formulation of Hou's Black Powder |
| 01/30/2013 | CN102895618A Preparation technology and production method for integrated new formulation of snakegourd root and cassia twig decoction |
| 01/30/2013 | CN102895573A Medicament for treating fundus hemorrhage |
| 01/30/2013 | CN102895488A Chinese medicinal composition for treating livestock keratitis |
| 01/30/2013 | CN102895417A Preparation method of pinkeye wash water |
| 01/30/2013 | CN102895361A Pearl powder-cantharis dizzy pain patch |
| 01/30/2013 | CN102895346A Fumigating medicament for treating conjunctivitis |
| 01/30/2013 | CN102895330A Eyedrops for treating conjunctivitis |
| 01/30/2013 | CN102895313A Traditional Chinese medicine composition for treating diseases of ophthalmology and otorhinolaryngology |
| 01/30/2013 | CN102895234A Ocular allergy treatments |
| 01/30/2013 | CN102085203B Ophthalmic preparation of levofloxacin and prednisolone acetate and preparation method thereof |
| 01/30/2013 | CN102085175B Ophthalmic gel and preparation method thereof |
| 01/29/2013 | US8361511 Tasteless nutritional supplement containing free amino acids |
| 01/29/2013 | CA2586807C Topical nepafenac formulations |
| 01/29/2013 | CA2460000C Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 01/24/2013 | WO2013013143A1 Fixed dose combination of bimatoprost and brimonidine |
| 01/24/2013 | WO2013012692A1 Pharmaceutical compositions comprising plant-based polysaccharides and uses thereof |
| 01/24/2013 | WO2013011033A1 3-(fluorvinyl)pyrazoles and the use thereof |
| 01/24/2013 | WO2012112699A3 Method and apparatus for the delivery of photo-chemical (cross-linking) treatment to corneal tissue |
| 01/24/2013 | US20130023663 Substituted stilbenes and their reactions |
| 01/24/2013 | US20130023588 Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| 01/24/2013 | US20130023576 Pyrazole Compounds as CRTH2 Antagonists |
| 01/24/2013 | US20130023575 Compositions and methods for the treatment of ocular surface allergies |
| 01/24/2013 | US20130023573 Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| 01/24/2013 | US20130023572 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| 01/24/2013 | US20130023569 Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders |
| 01/24/2013 | US20130023562 Novel piperidine derivatives |
| 01/24/2013 | US20130023556 Autotaxin inhibitors |
| 01/24/2013 | US20130023550 Pharmaceutical compositions and methods of making same |
| 01/24/2013 | US20130023538 Heteroaryl Derivatives as CFTR Modulators |
| 01/24/2013 | US20130023536 Fixed dose combination of bimatoprost and brimonidine |
| 01/24/2013 | US20130023529 Methods Involving Aldose Reductase Inhibitors |
| 01/24/2013 | US20130023528 Prolylhydroxylase inhibitors and methods of use |
| 01/24/2013 | US20130023526 Isoxazolines as Therapeutic Agents |
| 01/24/2013 | US20130023524 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it |
| 01/24/2013 | US20130023520 Anaesthetic eye solution and method of use |
| 01/24/2013 | US20130023517 Therapeutic methods employing substituted piperidines which are CCR3 antagonists |